Pendolino Alfonso Luca, Ottaviano Giancarlo, Nijim Juman, Scarpa Bruno, De Lucia Giulia, Berro Cecilia, Nicolai Piero, Andrews Peter J
Department of ENT Royal National ENT & Eastman Dental Hospitals London UK.
Ear Institute University College London London UK.
Laryngoscope Investig Otolaryngol. 2022 Dec 2;8(1):46-54. doi: 10.1002/lio2.989.
No definitive treatment exists to effectively restore function in patients with persistent post-infectious olfactory dysfunction (OD). Corticosteroids have been considered as a therapeutic option in post-infectious OD but their benefit in COVID-19-related OD remains unexplored. We aim to determine the role of the combination of corticosteroids plus olfactory training (OT) in improving persistent COVID-19-related OD.
A multicenter real-life cohort study was conducted between December 2020 and April 2022 on patients with reported COVID-19-related OD. Only patients with confirmed OD at Sniffin' Sticks (S'S) and those who attended their 6-month follow-up were included. Patients were started on a combined treatment of corticosteroids and OT. Patients refusing corticosteroids or not doing any treatment formed the control groups. Visual analogue scale (VAS) for sense of smell and SNOT-22 were used to assess patients reported symptoms.
Sixty-seven subjects with reported COVID-19-related OD were initially seen. Normosmic patients at S'S ( = 14) and those not attending their follow-up ( = 9) were excluded. Of the 44 patients included in the analysis, 19 patients had the combined treatment (group A), 16 patients refused to take corticosteroids and did the OT alone (group B) whereas 9 patients did not do any treatment (group C). An improvement of threshold + discrimination + identification (TDI) score ( = .01) and VAS for smell ( = .01) was found in group A whereas only the TDI score improved in group B ( = .04). Presence of comorbidities, age, sex (male), and length of OD negatively influenced olfactory recovery.
Our study confirms the importance of OT in long-term OD suggesting that the addition of corticosteroids may give a benefit in terms of patient's perceived olfaction.
2b.
对于持续性感染后嗅觉功能障碍(OD)患者,尚无有效的确定性治疗方法能有效恢复其功能。皮质类固醇已被视为感染后嗅觉功能障碍的一种治疗选择,但其在新冠病毒感染相关嗅觉功能障碍中的益处仍未得到探索。我们旨在确定皮质类固醇联合嗅觉训练(OT)在改善持续性新冠病毒感染相关嗅觉功能障碍中的作用。
2020年12月至2022年4月,对报告有新冠病毒感染相关嗅觉功能障碍的患者进行了一项多中心真实队列研究。仅纳入在“嗅觉棒测试”(S'S)中确诊嗅觉功能障碍且进行了6个月随访的患者。患者开始接受皮质类固醇和嗅觉训练的联合治疗。拒绝使用皮质类固醇或未进行任何治疗的患者组成对照组。使用嗅觉视觉模拟量表(VAS)和嗅觉相关生活质量量表(SNOT-22)评估患者报告的症状。
最初共诊治了67例报告有新冠病毒感染相关嗅觉功能障碍的受试者。排除在“嗅觉棒测试”中嗅觉正常的患者(n = 14)和未进行随访的患者(n = 9)。在纳入分析的44例患者中,19例患者接受了联合治疗(A组),16例患者拒绝使用皮质类固醇,仅进行了嗅觉训练(B组),而9例患者未进行任何治疗(C组)。A组的阈值+辨别力+识别力(TDI)评分(P = 0.01)和嗅觉VAS评分(P = 0.01)有所改善,而B组仅TDI评分有所改善(P = 0.04)。合并症的存在、年龄、性别(男性)和嗅觉功能障碍的持续时间对嗅觉恢复有负面影响。
我们的研究证实了嗅觉训练在长期嗅觉功能障碍中的重要性,表明添加皮质类固醇可能在患者嗅觉感知方面带来益处。
2b。